CurrentCommunity Health Plan WashingtonPolicy MC.CP.MP.248

Facility-based Sleep Studies for Obstructive Sleep Apnea

Defines medical necessity criteria for facility-based polysomnography (PSG), split-night studies, and facility-based PAP titration (including hypoglossal nerve stimulation titration) for adults with suspected obstructive sleep apnea; applies to Medicare health plans affiliated with Centene/Community Health Plan Washington.

Policy Summary

PayerCommunity Health Plan Washington

PolicyFacility-based Sleep Studies for Obstructive Sleep Apnea

Policy CodePolicy MC.CP.MP.248

Change TypeNo material change noted

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization that documents suspected OSA and reason HSAT is inappropriate or documents prior HSAT failure before scheduling facility-based PSG or titration.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥18age for covered facility-based PSG

≥50BMI threshold

≤2/yrrepeat-study limit

4 codessupporting CPTs

95803not supported CPT

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria — Facility-based Sleep Studies and Titration

Initial facility-based PSG or split-night study (members ≥18)

Covered when ALL of the following are met

Initial PSG criteria: Member/enrollee is ≥ 18 years and has suspected obstructive sleep apnea (OSA)

Age requirement and suspected OSA per policy

HSAT inappropriate

HSAT not appropriate reasons: One or more of: HSAT not available; unable to operate or tolerate HSAT and no assistant available; previous HSAT negative or inadequate for diagnosis; previous HSAT negative or inadequate for autotitration of APAP; chronic opioid use; low pretest probability of OSA (e.g., BMI <30, Mallampati 1–2, no snoring, neck circumference <17 inches males/<16 inches females); mission-critical worker; BMI ≥ 50 kg/m2; presence of specified comorbid risk factors or signs/symptoms that suggest OSA or interfere with HSAT
Comorbid risk factors include moderate-severe chronic pulmonary disease, NYHA class III–IV heart failure, ventricular arrhythmia history, neurologic/neuromuscular disease, suspected non-respiratory sleep disorder, hypoventilation syndrome

Repeat facility-based PSG or split-night study (after initial PSG)

Covered when ALL of the following are met

Repeat PSG criteria: All criteria for initial facility-based PSG are met AND the requested study plus any prior studies total two or fewer in a rolling year

Document prior study count and the specific indication for repeat study

Indications for repeat testing: One of: oral appliance adjusted for fit requiring efficacy assessment; change of device for intolerance; assessment of PAP settings including persistent symptoms despite adherence (≥4 hours/night on ≥70% of nights over 30 days); significant weight loss (≥10%) to assess discontinuation of PAP; significant weight gain (≥10%) or recurrent symptoms to reassess PAP; postoperative assessment after upper airway surgery; re-establish diagnosis when remote history of OSA and not on PAP; new signs/symptoms with prior negative study

Facility-based CPAP/BiPAP titration for OSA

Covered when ONE of the following is met

Titration criteria: One of: member meets facility-based PSG criteria and has not attempted home-based APAP titration; OR member was diagnosed with OSA on HSAT and has documented failure of an APAP trial (e.g., downloaded compliance data)

Facility-based titration appropriate if home APAP titration not attempted or failed

Titration PSG for hypoglossal nerve stimulation (HNS)

Covered when ALL of the following are met

HNS titration timing: Titration polysomnography is performed between three and six months after hypoglossal nerve stimulator implantation3-6 months

Timing specified to calibrate device settings

Actigraphy

Actigraphy stance: Actigraphy testing alone is insufficient to support diagnosis of obstructive sleep apnea

CPT 95803 (actigraphy) is not supported for OSA diagnosis

Actigraphy testing performed as a standalone diagnostic modality is not supported for the diagnosis of obstructive sleep apnea (OSA). The policy explicitly identifies CPT 95803 (actigraphy testing, recording, analysis, interpretation, and report) as a code that does not support coverage for OSA diagnosis.

Use of actigraphy alone to diagnose OSA is considered to have insufficient evidence and therefore is not supported by this clinical policy. Actigraphy does not provide the multi-parameter physiologic monitoring available from polysomnography that is required for diagnostic accuracy in OSA evaluation.

Coverage under this clinical policy is a guide to medical necessity and does not guarantee payment. Actual coverage and prior authorization requirements are determined by the member's benefit documents, evidence of coverage, and applicable state and federal rules; the policy is subject to all terms, conditions, exclusions, and limitations in those coverage documents.

Coding and Limits

CPT codes that support coverageCPTCovered

95807	Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist.
95808	Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist.
95810	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist.
95811	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist.

CPT codes that do not support coverageCPTNot Covered

95803

Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording).

inv-11: Repeat-study limit — Requested and previous studies amount to two or less per rolling year

Repeat-study limitRequested study plus any previous studies amount to two or less per rolling year

Documentation requirementFor repeat studies, document prior study count (≤2 per rolling year) and specific clinical indication for repeat testing

Allowed indications (examples)Oral appliance adjustment, device change for intolerance, reassessment of PAP settings, significant weight change (≥10%), postoperative assessment, re-establish diagnosis after remote history, new symptoms after prior negative study

inv-12: BMI threshold — BMI ≥ 50 kg/m2

BMI thresholdBMI ≥ 50 kg/m2

Context for use

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior authorization determined by benefit contract

Coverage determinations, including whether prior authorization is required for facility-based polysomnography (PSG) or CPAP/BiPAP titration, are made in accordance with the member's benefit contract and the Health Plan's administrative policies. Providers should verify prior authorization requirements and submission processes with the member's specific benefit documents before scheduling services.

Prior authorization requirements (if any) vary by benefit plan and are determined by the member's contract
Check the member's evidence of coverage/certificate of coverage for prior authorization rules and contact the Health Plan as needed

Denial Risk

Denial triggers

Coverage decisions and payment are subject to all terms, conditions, exclusions, and limitations of the member's coverage documents. Failure to meet policy criteria or to follow contractual requirements may result in claim denial or lack of payment.

Definitions

inv-22: Polysomnography (PSG) — Continuous, concurrent monitoring and recording of sleep physiologic parameters with physician evaluation and interpretation; used to diagnose OSA

DefinitionContinuous, concurrent monitoring and recording of multiple physiologic parameters of sleep with physician evaluation and interpretation

Primary usesDiagnose sleep disorders (including OSA) and evaluate response to treatments such as CPAP; used for PAP titration and assessment of ongoing therapy

Study typesConducted as full-night or split-night studies; split-night allows diagnosis then immediate PAP titration the same night

inv-23: Obstructive sleep apnea (OSA) — Sleep-disordered breathing caused by partial or complete upper airway collapse, diagnosed by a threshold number of predominantly obstructive events

DefinitionSleep-disordered breathing caused by partial or complete collapse of the upper airway during sleep

Background

Obstructive sleep apnea (OSA) is a sleep-disordered breathing condition caused by repetitive upper airway collapse during sleep and commonly presents with symptoms such as daytime sleepiness, loud snoring, and witnessed apneas. Diagnosis requires sleep testing because OSA is defined by the number of predominantly obstructive respiratory events per hour in the context of symptoms or comorbidities. Polysomnography (PSG) is the comprehensive, facility-based standard that continuously records multiple physiologic signals with physician interpretation and is considered the gold standard for diagnosing OSA and for PAP titration. Home sleep apnea testing (HSAT) can be appropriate for selected high pretest-probability patients without significant comorbidities, but HSAT measures fewer physiologic variables and can miss events that PSG would detect. For hypoglossal nerve stimulation devices, the standard of care is a facility-based titration PSG performed approximately 3–6 months after device activation to calibrate stimulation settings and assess both efficacy and patient comfort.